三鑫医疗: 关于调整2024年限制性股票激励计划回购价格及回购注销部分限制性股票的公告

Core Viewpoint - The company has announced adjustments to the repurchase price of the 2024 restricted stock incentive plan and the repurchase and cancellation of certain restricted stocks due to changes in the eligibility of some incentive targets [1][10][11]. Summary by Sections Approval Procedures - The company has completed the necessary approval procedures for the 2024 restricted stock incentive plan, including discussions and approvals from the board and supervisory committee [1][3][10]. Repurchase and Cancellation Details - The repurchase involves 31.3250 million shares of restricted stock, with 19,000 shares being repurchased due to two individuals leaving the company and 12.325 million shares due to 29 individuals not meeting the release conditions [5][10][11]. Repurchase Price and Basis - The repurchase price is set at the grant price, which is 3.5 yuan per share. Adjustments to this price may occur based on the company's capital actions, such as dividends or stock splits [6][9][10]. Financial Impact - The repurchase and cancellation of restricted stocks are not expected to have a significant impact on the company's financial status or operational results, and the incentive plan will continue to be implemented [10][11]. Opinions from Committees - Both the board's remuneration and assessment committee and the supervisory committee have reviewed and approved the repurchase and cancellation actions, confirming compliance with relevant regulations [10][11][12].